Clinical Trial

TherApeutics in Early ProState Cancer (TAPS02)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-01-11; most recent amendment 2025-06-17.
Status change: Not Yet Recruiting → Recruiting 2023-04-27
Trial Details
NCT Number NCT05191680
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: University of Cambridge, Janssen-Cilag Ltd.
Conditions Prostate Cancer
Enrollment 90 participants
Start Date 2023-04-24
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-20